

## BÖLÜM 3

# FEKAL STOMA AÇILMASINI GEREKTİREN HASTALIKLAR: KOLOREKTAL KANSER

Semra BAĞRIAÇIK ALTINTAŞ<sup>1</sup>  
Emel CİHAN<sup>2</sup>

### GİRİŞ

Dünya Sağlık Örgütü Uluslararası Kanser Araştırmaları Merkezi'nin 2022 verilerine göre dünyada yaşa standardize edilmiş en sık görülen kanserler arasında kolorektal kanser her iki cinsiyette 4. sırada, erkeklerde 3. Sırada, kadınlarda 2. sırada (1) ve kanser kaynaklı ölümlerde her iki cinsiyette de 2. sırada yer almaktadır (2,3). Amerikan Kanser Birliği'nin 2022 yılı verilerine göre 160.470 yeni KRK vakası raporlandırılmıştır (3). Sağlık Bakanlığının Türkiye kanser istatistikleri 2017 yılı verilerine göre KRK; her iki cinsiyette en sık görülen kanserler arasında 3. sırada yer almaktadır. Sıklığı erkeklerde yüz binde 25,1 iken kadınlarda yüz binde 14,7'dir (4). Küresel kanser yükünün 2025 yılında 20 milyondan daha fazla yeni olgu ile gerçekleşeceği tahmin edilmekte (2,5) ve özellikle KRK insidansında iki kat artış beklenmektedir (6).

### KOLOREKTAL ADENOKARSİNOM ETİYOLOJİSİ

KRK, çoğunlukla kolonun veya rektumun herhangi bir yerini etkilemekle birlikte en sık inen kolonun alt kısmından, sigmoid kolondan ya da rektumdan gelişmektedir. KRK genellikle kolon veya rektum mukozasında oluşan poliplerden kaynaklanmaktadır. Tüm KRK'lar genellikle adenomatöz polip olarak başlayan adenokarsinomlardır (5). Adenokarsinom, kolon ve rektumdaki karsinomların

<sup>1</sup> Uzm. Hems. Sağlık Bilimleri Üniversitesi İzmir Bozyaka Eğitim ve Araştırma Hastanesi, semrabagriacik@gmail.com

<sup>2</sup> Dr. Öğr. Üyesi, Kütahya Sağlık Bilimleri Üniversitesi Sağlık Bilimleri Fakültesi Cerrahi Hastalıklar Hemşireliği AD., emel.cihann@gmail.com - emel.cihan@ksbu.edu.tr

**KAYNAKLAR**

1. World Health Organization (WHO), International Agency for Research on Cancer (IARC). Cancer Today. World Health Organization (WHO).
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021;71(3):209–49.
3. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin.* 2022;72(1):7–33.
4. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü Kanser Dairesi Başkanlığı. Kanser İstatistikleri [Internet]. [cited 2022 Sep 17]. Available from: [https://hsgm.saglik.gov.tr/depo/birimler/kanser-db/istatistik/Turkiye\\_Kanser\\_Istatistikleri\\_2017.pdf](https://hsgm.saglik.gov.tr/depo/birimler/kanser-db/istatistik/Turkiye_Kanser_Istatistikleri_2017.pdf)
5. Sawicki T, Ruszkowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Vol. 13, *Cancers*. Multidisciplinary Digital Publishing Institute; 2021. p. 2025.
6. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. *CA Cancer J Clin.* 2020;70(3):145–64.
7. Langman G, Loughrey M, Shepherd N, Quirke P. Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Pathology Standards and Datasets. *Color Dis.* 2017;19:74–81.
8. Ahnen DJ, Wade SW, Jones WF, Sifri R, Silveiras JM, Greenmyer J, et al. The increasing incidence of young-onset colorectal cancer: A call to action. Vol. 89, *Mayo Clinic Proceedings.* 2014. p. 216–24.
9. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJC. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. *Gut.* 2005;54(9):1283–6.
10. Karim S, Brennan K, Nanji S, Berry SR, Booth CM. Association between prognosis and tumor laterality in early-stage colon cancer. *JAMA Oncol.* 2017;3(10):1386–92.
11. Gandomani HS, Yousefi SM, Aghajani M, Mohammadian-Hafshejani A, Tarazoj AA, Pouyesh V, et al. Colorectal cancer in the world: incidence, mortality and risk factors. *Biomed Res Ther.* 2017;4(10):1656.
12. Johnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B, et al. Meta-Analyses of colorectal cancer risk factors. *Cancer Causes Control.* 2013;24(6):1207–22.
13. American Cancer Society. Colorectal Cancer Risk Factors [Internet]. [cited 2022 Sep 15]. Available from: <https://www.cancer.org/cancer/colon-rectal-cancer/causes-risks-prevention/risk-factors.html>
14. Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. *CA Cancer J Clin.* 2018;68(1):31–54.
15. Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG Clinical Guidelines: Colorectal Cancer Screening 2021. *Am J Gastroenterol.* 2021;116(3):458–79.
16. Patel SG, May FP, Anderson JC, Burke CA, Dominitz JA, Gross SA, et al. Updates on Age to Start and Stop Colorectal Cancer Screening: Recommendations From the U.S. Multi-Society Task Force on Colorectal Cancer. *Gastroenterology.* 2022;162(1):285–99.
17. Murphy G, Devesa SS, Cross AJ, Inskip PD, McGlynn KA, Cook MB. Sex disparities in colorectal cancer incidence by anatomic subsite, race and age. *Int J Cancer.* 2011;128(7):1668–75.
18. Jochem C, Leitzmann M. Obesity and colorectal cancer. In: *Recent Results in Cancer Research. Recent Results Cancer Res;* 2016. p. 17–41.
19. American Cancer Society. Can Colorectal Cancer Be Found Early? [Internet]. [cited 2022 Sep 15]. Available from: <https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/detection.html>
20. Karahalios A, Simpson JA, Baglietto L, MacInnis RJ, Hodge AM, Giles GG, et al. Change in weight and waist circumference and risk of colorectal cancer: Results from the Melbourne Collaborative Cohort Study. *BMC Cancer.* 2016;16(1).

21. Thanikachalam K, Khan G. Colorectal cancer and nutrition. Vol. 11, *Nutrients*. *Nutrients*; 2019.
22. Guérin A, Mody R, Fok B, Lasch KL, Zhou Z, Wu EQ, et al. Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation. *Aliment Pharmacol Ther*. 2014;40(1):83–92.
23. Power AM, Talley NJ, Ford AC. Association between constipation and colorectal cancer: Systematic review and meta-analysis of observational studies. *Am J Gastroenterol*. 2013;108(6):894–903.
24. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of Colorectal Cancer in Patients With Ulcerative Colitis: A Meta-analysis of Population-Based Cohort Studies. *Clin Gastroenterol Hepatol*. 2012;10(6):639–45.
25. Carchman E. Crohn's Disease and the Risk of Cancer. *Clin Colon Rectal Surg*. 2019;32(4):305–13.
26. Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, Lowenfels AB, et al. Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations. *Gastroenterology*. 2018;154(3):736–745.e14.
27. Yamada A, Komaki Y, Komaki F, Micic D, Zullo S, Sakuraba A. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. *Lancet Oncol*. 2018;19(6):758–67.
28. Overbeek JA, Kuiper JG, van der Heijden AAWA, Labots M, Haug U, Herings RMC, et al. Sex- and site-specific differences in colorectal cancer risk among people with type 2 diabetes. *Int J Colorectal Dis*. 2019;34(2):269–76.
29. Alsherdah N, Akhtar S. Diet, obesity and colorectal carcinoma risk: Results from a national cancer registry-based middle-eastern study 11 Medical and Health Sciences 1117 Public Health and Health Services. *BMC Cancer*. 2018;18(1):1–10.
30. Shaw E, Farris MS, Stone CR, Derksen JWG, Johnson R, Hilsden RJ, et al. Effects of physical activity on colorectal cancer risk among family history and body mass index subgroups: A systematic review and meta-analysis. *BMC Cancer*. 2018;18(1).
31. Dong Y, Zhou J, Zhu Y, Luo L, He T, Hu H, et al. Abdominal obesity and colorectal cancer risk: Systematic review and meta-analysis of prospective studies. *Biosci Rep*. 2017;37(6).
32. Zeng H, Umar S, Rust B, Lazarova D, Bordonaro M. Secondary bile acids and short chain fatty acids in the colon: A focus on colonic microbiome, cell proliferation, inflammation, and cancer. Vol. 20, *International Journal of Molecular Sciences*. *Int J Mol Sci*; 2019.
33. Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, et al. Alcohol consumption and site-specific cancer risk: A comprehensive dose-response meta-analysis. *Br J Cancer*. 2015;112(3):580–93.
34. Hurley S, Goldberg D, Nelson DO, Lu Y, Henderson K, Bernstein L, et al. Risk of colorectal cancer associated with active smoking among female teachers. *Cancer Causes Control*. 2013 Jul;24(7):1291–304.
35. American Cancer Society. Colorectal Cancer Screening Guidelines [Internet]. [cited 2022 Sep 15]. Available from: <https://www.cancer.org/health-care-professionals/american-cancer-society-prevention-early-detection-guidelines/colorectal-cancer-screening-guidelines.html>
36. Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. *CA Cancer J Clin*. 2018;68(4):250–81.
37. American Cancer Society. Colorectal cancer, early detection, diagnosis, and staging [Internet]. [cited 2022 Sep 15]. Available from: <https://www.cancer.org/content/dam/CRC/PDF/Public/8606.00.pdf>
38. Van Gossum A, Munoz-Navas M, Fernandez-Urien I, Carretero C, Gay G, Delvaux M, et al. Capsule Endoscopy versus Colonoscopy for the Detection of Polyps and Cancer. *N Engl J Med*. 2009;361(3):264–70.
39. Quirke P, West NP, Nagtegaal ID. EURECCA consensus conference highlights about colorectal cancer clinical management: The pathologists expert review. Vol. 464, *Virchows Archiv*. *Virchows Arch*; 2014. p. 129–34.

40. Van De Velde CJH, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blomqvist L, et al. EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum. *Eur J Cancer*. 2014;50(1):1.e1-1.e34.
41. Tudyka V, Blomqvist L, Beets-Tan RGH, Boelens PG, Valentini V, Van De Velde CJ, et al. EU-RECCA consensus conference highlights about colon & rectal cancer multidisciplinary management: the radiology experts review. *Eur J Surg Oncol*. 2014;40(4):469–75.
42. Song L, Li Y. SEPT9: A Specific Circulating Biomarker for Colorectal Cancer. *Adv Clin Chem*. 2015;72:171–204.
43. Sun J, Fei F, Zhang M, Li Y, Zhang X, Zhu S, et al. The role of mSEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer. *BMC Cancer*. 2019;19(1):1–10.
44. Weiser MR. AJCC 8th Edition: Colorectal Cancer. Vol. 25, *Annals of Surgical Oncology*. Ann Surg Oncol; 2018. p. 1454–5.
45. Dursun N, Paşaoğlu E. Changes and updates in staging colorectal carcinomas at american joint of cancer committee and cancer reporting protocol of college of american pathologists. *J Curr Pathol*. 2018;2(3):78.
46. Bonjer HJ, Deijen CL, Abis GA, Cuesta MA, van der Pas MHGM, de Lange-de Klerk ESM, et al. A Randomized Trial of Laparoscopic versus Open Surgery for Rectal Cancer. *N Engl J Med*. 2015;372(14):1324–32.
47. Willaert W, Cosyns S, Ceelen W. Biology-Based Surgery: The Extent of Lymphadenectomy in Cancer of the Colon. *Eur Surg Res*. 2019;59(5–6):371–9.
48. Jung DH, Park HJ, Jang HH, Kim SH, Jung YJ, Lee WS. Clinical Impact of PD-L1 Expression for Survival in Curatively Resected Colon Cancer. *Cancer Invest*. 2020;38(7):406–14.
49. Kingham TP, DeMatteo RP. Multidisciplinary Treatment of Gastrointestinal Stromal Tumors. Vol. 89, *Surgical Clinics of North America*. 2009. p. 217–33.
50. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, The ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2014;25:iii1–9.
51. Tam SY, Wu VWC. A review on the special radiotherapy techniques of colorectal cancer. *Front Oncol*. 2019;9:208.
52. American Cancer Society. Colorectal Cancer Chemotherapy [Internet]. [cited 2022 Sep 15]. Available from: <https://www.cancer.org/cancer/colon-rectal-cancer/treating/chemotherapy.html>
53. Rahbari NN, Elbers H, Askoxylakis V, Mutschall E, Bork U, Bü Chler MW, et al. Neoadjuvant radiotherapy for rectal cancer: Meta-analysis of randomized controlled trials. *Ann Surg Oncol*. 2013;20(13):4169–82.
54. García M, Martínez-Villacampa M, Santos C, Navarro V, Teule A, Losa F, et al. Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer. *BMC Cancer*. 2015;15(1):1–9.
55. Çokmert S, Altun Z, Öztop İ, Aktaş S, Olgun N. Kolorektal Kanser ve İmmünoterapi. *DEÜ Tıp Fakültesi Derg*. 2016;30(3):131–7.
56. Wound Ostomy and Continence Nurses Society. Wound, Ostomy and Continence Nurses Society™ core curriculum: Continence management. In: *Wound, Ostomy and Continence Nurses Society™ Core Curriculum: Continence Management*. 2016. p. 1–368.
57. Avital S, Romaguera RL, Sands L, Marchetti F, Hellinger MD. Primary malignant melanoma of the right colon. *Am Surg*. 2004;70(7):649–51.
58. Giordano V, Iovino P, Corvese F, Vellone E, Alvaro R, Villa G. Caregiver contribution to self-care and its associated variables among caregivers of ostomy patients: Results of a cross-sectional study. *J Clin Nurs*. 2022;31(1–2):99–110.
59. Claessens I, Probert R, Tielemans C, Steen A, Nilsson C, Andersen BD, et al. The Ostomy Life Study: The everyday challenges faced by people living with a stoma in a snapshot. *Gastrointest Nurs*. 2015;13(5):18–25.